

mTORC1 controls glycogen synthase kinase 3 β nuclear localization and function

Stephen J. Bautista¹, Ivan Boras¹, Adriano Vissa^{3,4}, Noa Mecica¹, Christopher M. Yip^{3,5,6}, Peter K. Kim^{4,5} and Costin N. Antonescu^{1,2}

¹ Department of Chemistry and Biology and Graduate Program in Molecular Science, Ryerson University, Toronto Ontario, Canada, M5B 2K3

² Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada, M5B 1W8

³ Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada, M5S 3E5

⁴ Program in Cell Biology, The Hospital for Sick Children, Toronto, Ontario, Canada, M5G 0A4

⁵ Department of Biochemistry, University of Toronto, Toronto, Canada M5G 1X8

⁶ Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada, M5S 3E5

Running Title: mTORC1 regulates GSK3 β

Keywords: c-myc, snail, lysosome, metabolism, AMPK, Akt

Summary statement (15-30 words): GSK3 β nuclear localization and function is negatively regulated by the metabolic and mitogenic sensor mTORC1. mTORC1 control of GSK3 β localization requires Rab7 and lysosomal membrane traffic.

Abstract

Glycogen synthase kinase 3 β (GSK3 β) phosphorylates and regulates a wide range of substrates involved in diverse cellular functions. Some GSK3 β substrates, such as c-myc and snail, are nuclear-resident transcription factors, suggesting possible control of GSK3 β function by regulation of its nuclear localization. Inhibition of mechanistic target of rapamycin (mTORC1) led to partial redistribution of GSK3 β from the cytosol to the nucleus, and GSK3 β -dependent reduction of the expression of c-myc and snail. mTORC1 is controlled by metabolic cues, such as by AMP-activated protein kinase (AMPK) or amino acid abundance. Indeed AMPK activation or amino acid deprivation promoted GSK3 β nuclear localization in an mTORC1-dependent manner. GSK3 β was detected in several distinct endomembrane compartments, including lysosomes. Consistently, disruption of late endosomes/lysosomes through perturbation of Rab7 resulted in loss of GSK3 β from lysosomes, and enhanced GSK3 β nuclear localization as well as GSK3 β -dependent reduction of c-myc levels. This indicates that GSK3 β nuclear localization and function is suppressed by mTORC1, and suggests a new link between metabolic conditions sensed by mTORC1 and GSK3 β -dependent regulation of transcriptional networks controlling biomass production.

Introduction

Glycogen synthase kinase 3 β (GSK3 β) is a serine/threonine protein kinase that controls numerous aspects of cellular physiology such as proliferation, metabolism, and apoptosis (Beurel et al., 2015; Cormier and Woodgett, 2017; Doble and Woodgett, 2003; Sutherland, 2011). Dysregulation of GSK3 β has been linked to various diseases such as insulin resistance/diabetes, Alzheimer's disease and cancer (Jope and Johnson, 2004). GSK3 β phosphorylates over 100 substrates, more than the typical number of substrates for most kinases (Beurel et al., 2015; Linding et al., 2007; Sutherland, 2011), thus illustrating the broad capabilities for control of cell physiology by GSK3 β . Notably, GSK3 β is further distinguished from other kinases by being basally active (Doble and Woodgett, 2003). Hence, many mechanisms likely exist to regulate GSK3 β .

GSK3 β activity is indeed regulated by phosphorylation on S9, mediated by kinases such as Akt, protein kinase C (PKC), and p90RSK, resulting in negative regulation of GSK3 β activity (Cross et al., 1995; Delcommenne et al., 1998; Fang et al., 2000; Stambolic and Woodgett, 1994; Sutherland et al., 1993; Tsujio et al., 2000). Phosphorylation of other sites on GSK3 β may also suppress GSK3 β activity, such as that of S389 by p38 MAPK (Thornton et al., 2008). In addition to GSK3 β phosphorylation, control of GSK3 β action may be achieved by localization of GSK3 β or some of its substrates into distinct cellular compartments, such as the nucleus, such that GSK3 β may have limited and regulated access to certain substrates (Bechard and Dalton, 2009; Meares and Jope, 2007; Sutherland, 2011).

Several GSK3 β substrates are transcription factors (Sutherland, 2011) localized largely to the nucleus, including c-myc (Gregory et al., 2003), snail (Zhou et al., 2004), C/EBP α and β (Ross et al., 1999; Tang et al., 2005), and CREB (Fiol et al., 1994). C-myc controls genes important for proliferation, metabolism and biomass production, and stem-cell self renewal (reviewed by (Dang, 2012; Dang et al., 2009; Kalkat et al., 2017)). Moreover, c-myc is an oncogene altered in many cancers (Kalkat et al., 2017), highlighting the need for precise regulation of its function. C-myc protein levels are controlled by GSK3 β -dependent phosphorylation of T58 on c-myc (Gregory et al., 2003), leading to ubiquitin-dependent proteosomal degradation (Thomas and Tansey, 2011). Control of phosphorylation and/or degradation of these nuclear substrates by GSK3 β may involve modulation of GSK3 β nuclear

localization. However, the identity of the cellular compartments in which GSK3 β is localized, and how it moves from various cellular compartments to the nucleus is not well defined.

GSK3 β localizes in part to membrane compartments in the cytoplasm. It is recruited to the plasma membrane via association with Axin (Zeng et al., 2008), impacting Wnt signaling to β -catenin (Wu and Pan, 2010). GSK3 β is also detected on APPL1 early endosomes (Schenck et al., 2008). APPL1 acts as an adaptor protein to recruit Akt, facilitating GSK3 β phosphorylation and inactivation on these early endosomes, thus impacting clathrin-mediated endocytosis (Reis et al., 2015) and cell survival (Schenck et al., 2008). GSK3 β also localizes to lysosomes (Li et al., 2016) and controls lysosomal acidification (Azoulay-Alfaguter et al., 2015). Hence, GSK3 β may localize to multiple distinct endomembrane compartments including the plasma membrane, early endosomes and lysosomes, with distinct functions at each locale.

GSK3 β exhibits nuclear localization under certain conditions including in response to apoptotic signals induced by heat shock or staurosporine treatment (Bijur and Jope, 2001), S-phase of the cell cycle (Diehl et al., 1998), replicative senescence in fibroblasts (Zmijewski and Jope, 2004), and loss of phosphatidylinositol-3-kinase (PI3K)-Akt signaling in embryonic stem cells (Bechard and Dalton, 2009). Site-directed mutagenesis studies revealed that nuclear localization of GSK3 β requires a bipartite nuclear localization sequence (NLS) contained within residues 85-103 on GSK3 β , and that nuclear localization was also modulated by the N-terminal 9 amino acids on GSK3 β (Meares and Jope, 2007).

Collectively, these observations raise the question of whether the control of GSK3 β nucleocytoplasmic shuttling could be an important mechanism to control its function by modulating access to nuclear substrates. Indeed nuclear localization of GSK3 β induced by inhibition of PI3K or Akt leads to GSK3 β -dependent phosphorylation of c-myc, leading to its degradation (Bechard and Dalton, 2009). However, it is not clear how PI3K-Akt signals impact GSK3 β localization. Since this N-terminal region contains the S9 phosphorylation site, it is possible that Akt or other kinases capable of phosphorylation of this residue impact nuclear localization of GSK3 β , although a GSK3 β mutant (S9A) did not show obvious differences in nuclear localization (Meares and Jope, 2007).

While Akt may control GSK3 β localization via direct phosphorylation of GSK3 β on S9, this may be indirect and result from Akt-dependent activation of other signals, downstream of Akt, such as the mechanistic target of rapamycin complex 1 (mTORC1). Mitogenic activation of

PI3K-Akt signals leads to inhibition of the Tuberous Sclerosis Complex 1/2 (TSC 1/2) (Inoki et al., 2002), activation of the GTPase Rheb (Inoki et al., 2003), and thus mTORC1 activation (Long et al., 2005; Tee et al., 2003). mTORC1 in turn controls many processes including metabolism, protein synthesis, cell growth and autophagy (recently reviewed by (Saxton and Sabatini, 2017)). In addition to mitogenic control, mTORC1 is also strongly controlled by metabolic cues. Amino acid levels are sensed by a mechanism involving the lysosomal V-ATPase and other sensors, leading to the recruitment and activation of mTORC1 at the lysosome under conditions of amino acid sufficiency (Bar-Peled et al., 2012; Zoncu et al., 2011). Further, activation of AMP-activated protein kinase (AMPK) by energy insufficiency, resulting from an increase in the cellular levels of AMP and ADP relative to ATP, leads to phosphorylation and activation of TSC2, thus suppressing mTORC1 (Inoki et al., 2006; Shaw et al., 2004). Hence, mitogenic and metabolic signals control mTORC1 activation.

While it is not known if PI3K-Akt signaling regulates GSK3 β nuclear localization *via* engagement of mTORC1, several studies have reported that GSK3 β enhances mTORC1 activity. GSK3 β phosphorylates the mTORC1 subunit Raptor (Stretton et al., 2015), resulting in enhanced mTORC1 activity (Azoulay-Alfaguter et al., 2015; Stretton et al., 2015). GSK3 β also negatively regulates mTORC1 signaling by binding (Ka et al., 2014) and phosphorylation of TSC2 (Inoki et al., 2006). Moreover, GSK3 β binds to and regulates AMPK (Suzuki et al., 2013). Hence, GSK3 β controls the mTORC1 and AMPK metabolic and mitogenic sensors. However, the possibility of a reciprocal regulation of GSK3 β by signals from mTORC1 and AMPK, impacting GSK3 β nuclear localization and thus access to substrates therein such as c-myc, has so far been unexamined.

Here, we examine mTORC1 regulation of GSK3 β nuclear localization and function. To do so, we use pharmacological and other approaches to manipulate mitogenic or metabolic signals and examine GSK3 β localization to various endomembrane compartments and nucleus as well as GSK3 β -dependent functions associated with nuclear GSK3 β . We find a novel regulatory axis sensing mitogenic signals, metabolic cues and membrane traffic at the late endosome/lysosome that modulates GSK3 β nuclear localization and function.

Results

The PI3K-Akt signaling pathway controls GSK3 β nucleocytoplasmic shuttling and thus access of GSK3 β to nuclear targets either directly or via activation of the downstream kinase mTORC1. mTORC1 integrates both mitogenic (PI3K-Akt) and metabolic cues, and is localized to the lysosome once activated. Using a variety of strategies to manipulate mitogenic and metabolic signals converging on mTORC1 and lysosomal membrane traffic, we examined how mTORC1 regulates GSK3 β nuclear access and function.

mTORC1 controls GSK3 β nuclear localization and c-myc expression

To determine whether mTORC1 regulates GSK3 β localization and function downstream of PI3K/Akt, we first examined the effect of the mTORC1 inhibitor rapamycin on c-myc expression. Treatment of ARPE-19 cells (RPE henceforth) with 1 μ g/mL rapamycin caused a time-dependent decrease in c-myc expression, reaching $57 \pm 4.8\%$ after 2 hours of rapamycin treatment ($n = 6$, $p < 0.05$, **Fig. 1A**). Importantly, co-treatment with 10 μ M of the GSK3 β kinase inhibitor CHIR99021 blunted the decrease in c-myc expression elicited by rapamycin treatment (**Fig. 1A**). Consistent with this result, rapamycin treatment also elicited a reduction in expression of the transcription factor snail, an effect also blunted by co-treatment with CHIR 99021 (**Fig. 1B**).

We next used siRNA gene silencing of GSK3 β , which resulted in a $91 \pm 4.7\%$ reduction of GSK3 β protein levels ($n = 3$, $p < 0.05$, **Fig. S1A**). While RPE cells also express the paralog GSK3 α , silencing of GSK3 β was specific and did not impact expression of GSK3 α (**Fig. S1B**). Cells subjected to silencing of GSK3 β exhibited no change in c-myc upon inhibition of sequential signals in the PI3K-Akt-mTORC1 axis, achieved by treatment with either LY294002, Akti-1/2, or rapamycin, respectively (**Fig. 1C**). In contrast, each inhibitor effectively reduced c-myc expression in cells subjected to non-targeting (control) siRNA treatment (**Fig. 1C**). Taken together, these results indicate that PI3K-Akt signals converge on mTORC1 to enhance c-myc levels in a manner that requires the regulation of GSK3 β .

To determine how PI3K-Akt-mTORC1 signals control c-myc expression in a GSK3 β -dependent manner, we examined the localization and levels of endogenous GSK3 β and c-myc.

Consistent with a previous report (Bechard and Dalton, 2009), in cells grown in serum with an active PI3K-Akt-mTORC1 axis, GSK3 β primarily localizes within the cytosol and appears mostly excluded from the nucleus (**Fig. 2A**). We confirmed the specificity of detection of endogenous GSK3 β by immunofluorescence microscopy following GSK3 β silencing (**Fig. S1C**). In contrast, and as expected (Abrams et al., 1982; Hann et al., 1983; Smith et al., 2004), c-myc localizes virtually entirely within the nucleus under these conditions (**Fig. 2A**). Thus, under conditions in which mTORC1 is active, GSK3 β and c-myc are compartmentalized separately within the cytosol and nucleus, respectively.

We next determined how PI3K-Akt-mTORC1 signaling regulates GSK3 β localization. Treatment of RPE cells with either LY294002, Akti-1/2, or rapamycin to perturb PI3K, Akt or mTORC1, respectively resulted in robust and significant ($n = 3$, $p < 0.05$) increase in nuclear GSK3 β , measured by the ratio of nuclear to cytosolic mean fluorescence intensities of GSK3 β which we term the GSK3 β nuclear localization index (**Fig. 2B**). Importantly, the effect of rapamycin treatment on GSK3 β nuclear translocation and snail protein levels was also observed in MDA-MB-231 breast cancer cells (**Fig. S1D-E**), demonstrating that the mTORC1-dependent control of GSK3 β is not unique to RPE cells. Furthermore, inhibition of the PI3K-Akt-mTORC1 axis also resulted in robust nuclear localization of GSK3 α (**Fig. S1E**), a paralog of GSK3 β with highly similar kinase domains but unique terminal motifs (Cormier and Woodgett, 2017; Woodgett, 1990). These results indicate that PI3K-Akt signals act via control of mTORC1 to regulate GSK3 β nuclear localization, as well as that of GSK3 α .

To test the importance of Ran in mTORC1-dependent GSK3 β nuclear translocation, we examined the impact of Ran GTP-binding mutants on GSK3 β localization. We expressed wild-type (WT) Ran or one of two Ran mutants, Ran T24N and G19V, which are constitutively GDP- or GTP-bound, respectively (Carey et al., 1996). Cells expressing WT Ran exhibited little nuclear GSK3 β in the control condition, but a robust localization of GSK3 β in the nucleus was observed upon treatment with rapamycin (**Fig. 3**, upper panels, and quantification, lower panel). In contrast, cells expressing Ran T24N exhibited nuclear GSK3 β in both control and rapamycin-treated conditions (**Fig. 3**), consistent with Ran-GDP acting to facilitate nuclear import (Carey et al., 1996). Further, cells expressing Ran G19V exhibited mostly cytosolic GSK3 β in both control and rapamycin-treated conditions, consistent with this mutant blocking Ran-dependent nuclear

import (**Fig. 3**). These results indicate that GSK3 β undergoes Ran-dependent nucleocytoplasmic shuttling and Ran-dependent nuclear import that is regulated by mTORC1.

Metabolic cues regulate GSK3 β nuclear localization via mTORC1

As mTORC1 is regulated by both mitogenic (PI3K-Akt) signals as well as metabolic cues, we next examined how each of these signals contributes to the control of GSK3 β nuclear localization. AMPK is activated via ATP insufficiency, and negatively regulates mTORC1 signaling through phosphorylation and activation of TSC2 (Inoki et al., 2006; Shaw et al., 2004). Consistent with the effects of mTORC1 inhibition by rapamycin, treatment with the AMPK activator A769662 resulted in robust GSK3 β nuclear localization (**Fig. 4A**). Importantly, AMPK and mTORC1 exhibit reciprocal negative regulation (Inoki et al., 2012). As such, GSK3 β nuclear localization could conceivably be the direct result of loss of mTORC1 signals, or an increase in AMPK activation, both of which would be expected to occur upon treatment with either rapamycin or A769662. To dissect a role for mTORC1 versus AMPK in control of GSK3 β nuclear localization, we used the AMPK inhibitor compound C (Ross et al., 2015). Cells treated with compound C exhibited a rapamycin-dependent increase in GSK3 β nuclear localization comparable to that observed in cells treated with rapamycin but not compound C (**Fig. 4A**). This indicates that AMPK activity is dispensable for GSK3 β nuclear localization induced by mTORC1 inhibition. As GSK3 β forms a complex with AMPK (Suzuki et al., 2013), we also tested whether AMPK may have a kinase-independent, structural role in regulation of GSK3 β . However, silencing of AMPK did not impact GSK3 β nuclear localization (**Fig. S2**). Collectively, these results indicate that while AMPK activation also triggers an accumulation of nuclear GSK3 β , this occurs as a result of AMPK-dependent inhibition of mTORC1 signals, and not as a result of direct action of AMPK on GSK3 β nuclear localization.

mTORC1 is activated by abundance of amino acids in a manner that requires the V-ATPase (Zoncu et al., 2011). To determine how amino acid-dependent activation of mTORC1 impacted control of GSK3 β localization, we treated cells with the V-ATPase inhibitor Concanamycin A. Cells treated with Concanamycin A exhibited a significant enhancement of nuclear GSK3 β relative to control (**Fig. 4B**). Consistent with this result, amino acid deprivation achieved via treatment of cells in amino acid depleted media (EBSS) also mimicked the effect of rapamycin

treatment in RPE (**Fig. 4C**) as well as MDA-MB-231 (**Fig. S1C**) cells. These results indicate that amino acid sensing by mTORC1 contributes to the regulation of GSK3 β nuclear localization.

mTORC1 inhibition also leads to induction of autophagy (Jung et al., 2009). We therefore tested whether autophagy is required for GSK3 β nuclear localization upon mTORC1 inhibition with rapamycin. To inhibit autophagy induction, we treated cells siRNA targeting endogenous ULK (Saric et al., 2016), which resulted in a robust $77\% \pm 6.2$ reduction of ULK expression ($n = 3$, $p < 0.05$, **Fig. S3A**). Cells treated with siRNA to silence ULK1 exhibited cytosolic GSK3 β , which relocalized to the nucleus upon rapamycin treatment in a manner indistinguishable from cells treated with non-targeting siRNA (**Fig. S3B**). As autophagy induction has also been reported to lead to c-myc degradation (Cianfanelli et al., 2014), we also tested the effect of ULK1 silencing on rapamycin-induced c-myc expression. Surprisingly, silencing of ULK1 on its own reduced c-myc expression (**Fig. 3C**). Moreover, and in contrast to the findings of a previous study (Cianfanelli et al., 2014), impairment of autophagy induction by ULK1 silencing did not prevent the rapamycin-induced reduction in c-myc expression (**Fig. S3C**). Thus, GSK3 β nuclear translocation and c-myc degradation observed upon mTORC1 inhibition are largely independent of autophagy induction. Instead, c-myc degradation upon mTORC1 inhibition is mediated by regulation of GSK3 β nuclear localization and function.

Control of GSK3 β nuclear localization does not require GSK3 β S9 phosphorylation

Akt phosphorylates GSK3 β on S9, which negatively regulates GSK3 β kinase activity towards certain substrates. We next examined how GSK3 β phosphorylation may contribute to control of GSK3 β nuclear localization by mTORC1. As expected, cells treated with LY294002 or Akti-1/2 exhibited significant reductions in GSK3 β S9 phosphorylation by $80 \pm 0.8\%$ and $60 \pm 6.8\%$ respectively ($n = 3$, $p < 0.05$, **Fig. 5A**). In contrast, cells treated with rapamycin exhibited no change in GSK3 β S9 phosphorylation compared to control (**Fig. 5A**). These results uncouple S9 phosphorylation from control of GSK3 β nuclear localization. To directly probe the contribution of GSK3 β S9 phosphorylation to mTORC1-dependent GSK3 β nuclear localization, we studied the subcellular localization of GSK3 β S9A. Under basal conditions, GSK3 β S9A remains cytosolic, while treatment with the Akt inhibitor Akti-1/2 resulted in nuclear localization of GSK3 β S9A, as seen with GSK3 β WT (**Fig. 5B**).

Using phos-tag acrylamide electrophoresis, a technique that exaggerates differences in apparent molecular weight of phosphorylated species of a protein (Kinoshita et al., 2006), we observed two detectable species of GSK3 β , of which the higher molecular weight species likely corresponds to the S9 phosphorylated form given its sensitivity to PI3K and Akt inhibition (**Fig. S4A**). In contrast and as expected, rapamycin had no effect on GSK3 β detected by this method. Collectively, these results indicate that regulation of GSK3 β S9 phosphorylation does not contribute to control of GSK3 β nuclear localization by PI3K-Akt-mTORC1 signals.

GSK3 β is localized to several distinct membrane compartments within the cytoplasm

Active mTORC1 is recruited to the surface of the lysosome (Sancak et al., 2008). Together with our observations that mTORC1 controls GSK3 β nuclear localization, this suggests that (i) mTORC1 control of GSK3 β may occur at lysosomes and (ii) control of GSK3 β nuclear localization by mTORC1 may require lysosomal membrane traffic. To determine if a pool of GSK3 β is indeed localized to lysosomes concomitantly to GSK3 β recruitment to other endomembrane compartments, we systematically examined the localization of endogenous GSK3 β relative to APPL1 and EEA1 early endosomes, and to lysosomes demarked by LAMP1. We observed punctate distribution of endogenous GSK3 β within the cytoplasm, with some visible overlap with each of APPL1, EEA1 and LAMP1 (**Fig. 6A-C**, left panels). To determine if the overlap observed between GSK3 β and each marker was specific, we used quantification by Manders' coefficient to compare overlap between real pairs of image channels, as well as between pairs of images with scrambled channel spatial position. This revealed specific GSK3 β recruitment to each membrane compartment (**Fig. 6A-C**). We performed a similar colocalization analysis of the image data using Pearson's coefficient and obtained similar results (**Fig. S4B**). This indicates that GSK3 β indeed exhibits partial yet specific localization to several distinct endomembrane compartments, including APPL1 and EEA1 early endosomes, and late endosomes/lysosomes demarked by LAMP1.

To further examine how GSK3 β may localize to lysosomes, we employed structured illumination microscopy (SIM). Using this method, we were able to resolve the limiting membrane of lysosomes demarked by LAMP1 fluorescence staining (**Fig. 6D**). Importantly, GSK3 β fluorescence staining was readily observed in punctate structures, in part associated with

the limiting membrane of the lysosome. These results indicate that a subset of GSK3 β in the cytoplasm exhibits association with the lysosome, either restricted to sub-domains of the lysosomal surface (Kaushik et al., 2006) or in structures associated with the lysosome, such as within membrane contact sites (Chu et al., 2015).

Control of GSK3 β nuclear localization and c-myc expression requires normal lysosomal membrane traffic

Given the localization mTORC1 (Sancak et al., 2008) and partial localization of GSK3 β (**Fig. 6C-D**) to or near the lysosome, we next sought to determine the role of late endosome/lysosome membrane traffic to mTORC1-dependent control of GSK3 β nuclear localization. To do so, we used a Rab7 mutant that is constitutively GDP-bound (T22N), which disrupts membrane traffic at the late endosome/lysosome (Choudhury et al., 2002). Cells expressing Rab7 T22N exhibited a significant increase in nuclear GSK3 β , even in the absence of rapamycin treatment, compared to cells expressing Rab7 WT (**Fig. 7A**). Furthermore, cells expressing Rab7 T22N exhibited a depletion of GSK3 β from lysosomes, observed by overlap of endogenous GSK3 β and LAMP1, quantified by Manders' coefficient (**Fig. S4C**). In contrast to the nuclear accumulation of GSK3 β in cells expressing Rab7 T22N, silencing of APPL1 to disrupt early endosome membrane traffic did not impact GSK3 β nuclear localization (**Fig. S4D**). These results indicate that membrane traffic at the late endosome/lysosome may be important to organize mTORC1 signals leading to control of GSK3 β nuclear localization.

In order to determine the consequence of Rab7-dependent control of GSK3 β nuclear localization, we examined the effect of expression of Rab7 T22N on GSK3 β -dependent c-myc expression levels. Cells expressing Rab7 T22N exhibited a stark reduction in c-myc expression relative to cells expressing Rab7 WT (**Fig. 7B**). Importantly, treatment of cells expressing Rab7 T22N with the GSK3 β inhibitor CHIR 99021 restored c-myc expression levels to that observed in cells expressing Rab7 WT (**Fig. 7B**). Taken together, these results indicate that control of GSK3 β nuclear localization requires Rab7-dependent late endosome/lysosomal membrane traffic, reflecting perhaps the role of lysosomes as platform for mTORC1 signaling required to negatively regulate GSK3 β nuclear translocation.

Discussion

We identified that the nuclear localization of GSK3 β is regulated by mTORC1, such that conditions that reduce mTORC1 activity result in increased nuclear localization of GSK3 β , and increased GSK3 β -dependent degradation of nuclear substrates such as c-myc and snail. Furthermore, GSK3 β was partly but specifically localized to the surface of late endosomes/lysosomes, and perturbation of membrane traffic at the late endosomes/lysosomes disrupted GSK3 β nucleocytoplasmic shuttling and regulation of c-myc expression.

Localization of GSK3 β within multiple membrane compartments within the cytoplasm

Separate studies have reported that GSK3 β may localize to a number of distinct cellular compartments, including endomembranes, mitochondria and the nucleus (reviewed by (Beurel et al., 2015)). By a systematic, unbiased approach, we find that endogenous GSK3 β localizes to several distinct endomembrane compartments, including APPL1 endosomes, EEA1-positive early endosomes and LAMP1-positive late endosomes/lysosomes (**Fig. 6**). In each case, the overlap of GSK3 β immunofluorescence signal and that of each compartment marker is clearly limited and partial, with substantial proportions of each signal not exhibiting overlap (**Fig. 6A-C**). However, systematic and unbiased analysis of colocalization performed by Manders' (**Fig. 6A-C**) or Pearson's (**Fig. S4B**) coefficient analysis indicates that GSK3 β overlap with each compartment is specific and non-random. Moreover, the specific recruitment of GSK3 β to the limiting membrane of LAMP1-positive late endosomes/lysosomes is supported by images obtained by SIM (**Fig. 6D**), as well as by the observation that perturbation of late endosome/lysosome membrane traffic by expression of a dominant interfering mutant of Rab7 abolishes the overlap of GSK3 β with LAMP1 signals (**Fig. S4C**). Our observations are thus consistent with the notion that GSK3 β is localized to a number of distinct cellular compartments, with a minor pool that in some cases is <10% of total cellular GSK3 β , recruited to each such compartment at steady state.

Our observations are also consistent with previous studies showing GSK3 β localization to APPL1 endosomes (Schenck et al., 2008). APPL1 recruitment to a subset of internalized membranes formed by clathrin-mediated endocytosis precedes the acquisition of markers of the

EEA1 early endosome (Zoncu et al., 2009). This pool of GSK3 β within APPL1 endosomes may be specifically targeted by phosphorylation on S9 by Akt, as silencing of APPL1 abolishes Akt-dependent GSK3 β phosphorylation (Reis et al., 2015; Schenck et al., 2008). Notably, perturbation of APPL1 by silencing did not impact mTORC1-dependent control of GSK3 β nuclear localization (**Fig. S4D**), suggesting that the APPL1-localized pool of GSK3 β does not directly participate in the regulation of GSK3 β nuclear localization by mTORC1.

As mTORC1 localizes to the surface of late endosomes and lysosomes, the pool of GSK3 β on these membranes may be under the direct regulation by mTORC1 to control GSK3 β nucleocytoplasmic shuttling. Indeed a previous report had observed some overlap of GSK3 β and the lysosome (Li et al., 2016). However, GSK3 β may also be sequestered within intraluminal vesicles of multivesicular bodies in response to Wnt signaling (Taelman et al., 2010), raising the possibility that the overlap that we observed by spinning disc confocal microscopy between LAMP1-positive structures and GSK3 β (**Fig. 6C**) could reflect GSK3 β within intraluminal vesicles. However, examination of SIM images suggests that very little, if any, GSK3 β is observed within the lumen of LAMP1-positive structures (**Fig. 6D**), suggesting that LAMP1-localized GSK3 β is largely associated with the limiting membrane of these compartments. Moreover, perturbation of Rab7 disrupts the localization of GSK3 β and LAMP1 (**Fig. S4C**), yet Rab7 disruption does not impact the sequestration of material into intraluminal vesicles (Vanlandingham and Ceresa, 2009). The molecular mechanism(s) by which GSK3 β is recruited to lysosomes remains unknown, and is beyond the scope of this study. Our results thus add systematic analysis and quantification to indicate that a pool of GSK3 β is present on the limiting membrane of the lysosome, and suggesting that this pool may be subject to regulation by mTORC1, resulting in control of GSK3 β nuclear localization.

Mechanism of control of GSK3 β nuclear localization by mTORC1

We found that direct inhibition of any component of the PI3K-Akt-mTORC1 axis, or activation of AMPK to trigger mTORC1 inhibition results in an increase in GSK3 β nuclear localization. Moreover, perturbation of Rab7-dependent membrane traffic also resulted in an increase in GSK3 β nuclear localization, suggesting that in addition to mTORC1 signals, lysosomal traffic and/or organization is also required to control GSK3 β nuclear import.

Interestingly, we also observed that inhibition of PI3K-Akt-mTORC1 also increased nuclear localization of GSK3 α . Hence, it is likely that mTORC1 signals similarly gate GSK3 α and GSK3 β nuclear localization. Taken together, we propose that mTORC1 establishes a form of ‘molecular licencing’ for retention within the cytoplasm for GSK3 α and GSK3 β , resulting in nuclear exclusion under conditions of elevated mTORC1 activity. This molecular licencing could take the form of a post-translational modification of GSK3 α or GSK3 β , or of regulation of protein complex formation at specific subcellular locale(s).

GSK3 β undergoes nucleocytoplasmic shuttling, due to nuclear import in balance with FRAT-1-mediated nuclear export (Wiechens and Fagotto, 2001). Nuclear import of some (but not all) proteins is controlled by a gradient of GTP-bound and GDP-bound Ran that spans the nuclear membrane (Strambio-De-Castillia et al., 2010). By expression of mutants of Ran (**Fig. 3**), we show that the nucleocytoplasmic shuttling of GSK3 β is Ran-dependent. Nuclear import of GSK3 β resulting from mTORC1 inhibition by rapamycin was prevented in cells expressing Ran G19V mutant defective in GTP hydrolysis and thus defective in nuclear import. Hence, nuclear import of GSK3 β regulated by mTORC1 is Ran-dependent.

We examined whether the phosphorylation of S9 on GSK3 β could control its mTORC1-regulated nuclear localization; however, two observations strongly suggest that this is not the case: (i) inhibition of mTORC1 by rapamycin did not alter S9 phosphorylation of GSK3 β (**Fig. 5A**), and (ii) a mutant of GSK3 β that cannot be phosphorylated at this position (S9A) behaved similarly to wild-type with respect to mTORC1-dependent nuclear localization (**Fig. 5B**). GSK3 β can also be phosphorylated on a number of other residues, including Y216, which may result from auto-phosphorylation at the time of GSK3 β synthesis (Beurel et al., 2015). Further, GSK3 β can be phosphorylated at T43 (Ding et al., 2005) and S389 (Thornton et al., 2008) by Erk and p38 MAPK, respectively, each of which lead to reduction in GSK3 β activity. Notably, using a phos-tag gel electrophoresis approach, a technique that exacerbates the apparent molecular weight increase caused by phosphorylation, we were only able to resolve two bands for GSK3 β that likely correspond to S9 phosphorylated and non-S9 phosphorylated forms (**Fig. S4A**). It will be interesting to determine in future studies if and how phosphorylation at sites other than S9 are regulated by mTORC1 to control GSK3 β nuclear localization.

Other than phosphorylation, other modifications reported for GSK3 β include citrullination (Stadler et al., 2013) ADP-ribosylation (Feijs et al., 2013) and calpain cleavage

(Goñi-Oliver et al., 2007). Indeed, citrullination of R3 and R5 residues within GSK3 β is important for nuclear localization (Stadler et al., 2013). However, we observed that mTORC1 controls both GSK3 α and GSK3 β nuclear localization, and these two GSK3 paralogs differ at their N-terminus within the region of GSK3 β that undergoes citrullination. Hence, it appears unlikely to expect that mTORC1 controls citrullination of GSK3 β as a mechanism of control of its nucleocytoplasmic shuttling. While beyond the scope of this study, it will be interesting to note how future work may resolve whether mTORC1-dependent regulation of post-translational modification of GSK3 β underlies the regulation of its nuclear localization by mTORC1.

mTORC1-dependent control of GSK3 β nuclear localization may occur as a result of regulation of GSK3 β interaction with other proteins in various endomembrane compartments. It is worth noting that the vast majority of cytoplasmic, but not nuclear GSK3 β , is associated with other protein(s) (Meares and Jope, 2007). Thus, it is possible that control of GSK3 β nucleocytoplasmic shuttling involves regulation of protein-protein interactions that serve to occlude the bipartite NLS of GSK3 β (residues 85 to 103) (Meares and Jope, 2007), thus limiting GSK3 β nuclear localization when these interactions are present.

We also found that Rab7 is required to retain GSK3 β in the cytoplasm under conditions when mTORC1 is otherwise active. Importantly, disruption of late endosome/lysosome membrane traffic by perturbations of Rab7 or other proteins does not impact mTORC1 activity (Flinn et al., 2010). This indicates that the ability of mTORC1 to limit the nuclear localization of GSK3 β requires active traffic to the late endosome/lysosome. This in turn suggests that the protein interactions engaged by GSK3 β that occlude its NLS and thus limit nuclear localization may occur on the lysosome, consistent with our observed localization of GSK3 β to the lysosome. Indeed GSK3 α and GSK3 β have nearly identical kinase domains (in which the NLS is found), consistent with the ability of mTORC1 to gate nuclear access for both GSK3 paralogs.

Furthermore, our observations that mTORC1 controls GSK3 β nuclear localization add to previous reports that GSK3 β activates mTORC1 signals (Inoki et al., 2006), and suggests the existence of reciprocal regulation of mTORC1 and GSK3 β . Overall, we propose that mTORC1 signals limit the ability of GSK3 β to localize to the nucleus, and that this may result from mTORC1-dependent control of GSK3 β interactions with other proteins in a manner that regulates occlusion of the NLS of GSK3 β at the lysosome.

Regulation of GSK3 β nuclear functions by mTORC1

We identified that various metabolic and mitogenic signals gate nuclear access for GSK3 β . This in turn allows for GSK3 β -dependent regulation of nuclear substrates in response to mTORC1 signals. Previous studies reported that nuclear and cytoplasmic pools of GSK3 β have distinct functions, such as nuclear GSK3 β facilitating stem cell differentiation over self-renewal (Bechard and Dalton, 2009) or the cytosolic pool of GSK3 β being sufficient to mediate GSK3 β -dependent cell survival to tumor necrosis factor α (TNF α) apoptotic signals (Meares and Jope, 2007).

One of the nuclear substrates of GSK3 β is c-myc, a helix-loop-helix-leucine zipper transcription factor that has a very short half-life (15-30 mins) (Kalkat et al., 2017; Lüscher and Eisenman, 1988). As previously reported, nuclear localization of GSK3 β is required for phosphorylation of GSK3 β on T58, resulting in enhanced c-myc degradation (Gregory et al., 2003). We show that rapamycin treatment, which promotes nuclear localization of GSK3 β , also results in an acute reduction in c-myc accumulation (**Fig. 1**), most likely due to c-myc degradation. A previous report suggested that rapamycin treatment elicits degradation of c-myc by induction of autophagy, as result of induction of AMBRA-dependent dephosphorylation of c-myc at T58 (Cianfanelli et al., 2014). However, we show that the degradation of c-myc induced by rapamycin is insensitive to impairment of autophagy induction elicited by siRNA gene silencing of ULK1 (**Fig. S3**). Moreover, we find that the rapamycin-induced reduction in c-myc levels is countered by perturbation of GSK3 β (**Fig. 1A-B**). Hence, our results indicate that mTORC1-dependent control of GSK3 β nuclear localization regulates c-myc in a manner that does not require induction of autophagy.

Based on the control of GSK3 β nuclear localization by mTORC1 leading to control of c-myc, we propose the existence of a metabolic sensing signaling network that links nutrient availability with biomass production and proliferation. Indeed, c-myc controls the expression of many genes, generally to promote ribosome production, biomass accumulation and enhanced cellular bioenergetics, such as through mitochondrial biosynthesis (Miller et al., 2012). Furthermore, c-myc promotes epithelial-mesenchymal transition (Cho et al., 2010). Hence, signals activated during nutrient deficiency can impair the anabolic c-myc-dependent promotion

of biomass accumulation via this novel mTORC1-GSK3 β -c-myc signaling axis involving control of GSK3 β nuclear localization.

GSK3 β may also regulate other nuclear substrates selectively during conditions of reduced mTORC1 signaling or other states in which GSK3 β exhibits nuclear localization. Collectively, regulation of other GSK3 β substrates such as snail (leading to degradation, (Sekiya and Suzuki, 2011)) or c-jun (leading to impaired DNA binding, (Nikolakaki et al., 1993)) is consistent with the effect of GSK3 β -dependent degradation of c-myc: reduced cell cycle progression, impairment of epithelial-mesenchymal transition and/or reduced biomass accumulation. While examination of mTORC1-dependent regulation of all known GSK3 β nuclear targets is beyond the scope of this study, it is perhaps tempting to speculate that metabolic and mitogenic signals broadly control the nuclear profile of GSK3 β functions, coordinating energy-demanding accumulation of biomass, cell cycle progression and growth with nutrient availability. As cancer cells exhibit heterogeneity of metabolic cues and signals, it is possible that differences in metabolism between cancer cells that result in distinct GSK3 β nuclear localization profiles may underlie in part the differences in response to drugs targeting GSK3 β in cancer, although this remains to be examined.

In conclusion, we identified that GSK3 β nucleocytoplasmic shuttling is controlled by both mitogenic signals such as PI3K-Akt and metabolic cues including amino acid or ATP availability as a result of mTORC1-dependent control of GSK3 β nuclear import. In addition, GSK3 β localized in part to the late endosome/lysosome and nuclear localization of GSK3 β was regulated by Rab7, suggesting that membrane traffic at late endosomes and lysosomes impacts signals leading to control of GSK3 β nuclear localization. Lastly, we propose that GSK3 β -dependent control of nuclear proteins by mTORC1 occurs by regulation of GSK3 β nuclear import, linking nutrient availability to control of energy-dependent transcriptional networks.

Materials and Methods

Materials

Antibodies targeting specific proteins were obtained as follows: GSK3 β , phospho-GSK3 β (S9) actin, HA-epitope, EEA1, LAMP1, APPL1, and ULK1 (Cell Signaling, Danvers, MA), and clathrin (Santa Cruz Biotechnology, Dallas, TX). Horseradish peroxidase or fluorescently-conjugated conjugated secondary antibodies were purchased from Cell Signaling Technology (Danvers, MA). DAPI Nuclear staining was purchased from ThermoFisher (Rockford, IL).

Ran cDNA constructs tagged to HA, including WT, T24N and G19V forms in pKH3 were generously provided by Dr. Ian Macara (Vanderbilt University School of Medicine, Nashville, TN) (Carey et al., 1996). GSK3 β cDNA constructs, including HA-tagged WT and S9A forms in pcDNA3 were generously provided by Dr. Jim Woodgett (Lunenfeld-Tanenbaum Research Institute/Mount Sinai Hospital, Toronto, ON) (Stambolic and Woodgett, 1994). Rab7 constructs, including WT and T22N, were generously provided by Dr. Richard Pagano (Mayo Clinic and Foundation, Rochester, MN) (Choudhury et al., 2002).

Cell lines, cell culture and inhibitor treatment

Wild-type human retinal pigment epithelial cells (ARPE-19; RPE herein) were cultured were obtained from American Type Culture Collection (ATCC, Manassas, VA) as previously described (Delos Santos et al., 2017) with DMEM/F12 (Gibco, ThermoFisher Scientific, Waltham, MA) containing 10 % fetal bovine serum, 100 U/ml penicillin and 100 μ g/ml streptomycin. Cells were then incubated at 37 C and 5 % CO₂. MDA-MB-231 cells were obtained from ATCC and cultured as previously described (Fekri et al., 2016) with RPMI media 1640 (Gibco) containing 10 % fetal bovine serum, 100 U/ml penicillin and 100 μ g/ml streptomycin and incubated at 37C and 5 % CO₂.

All inhibitor treatments were performed (alone or in combination) for 1 h prior to experimental assays unless otherwise indicated, as follows: 10 μ M CHIR 99021 (Abcam, Cambridge, MA), 1 μ M Rapamycin (BioShop, Burlington, ON), 10 μ M LY294002 (Cell

Signaling Technologies), 5 μ M Akti-1/2 (Sigma-Aldrich, Oakville, Canada), 1 μ M Concanamycin A (BioShop). Amino acid starvation was performed by incubation in Earle's Balanced Salt Solution (EBSS, Gibco).

Plasmid and siRNA transfections

To perform DNA plasmid transfections, Lipofectamine 2000 (ThermoFisher Scientific) was used according to the manufacturers instructions and as previous described (Bone et al., 2017). Briefly, cells were incubated for 4 h with Lipofectamine 2000 reagent and appropriate plasmid in Opti-MEM (Gibco) at a 3:1 ratio. Subsequently, this transfection solution was removed, and cells were incubated in fresh cell growth medium at 37C and 5% CO₂ for 16-24 h prior to experimentation.

To perform siRNA transfections as previously described (Bone et al., 2017), custom-synthesized siRNAs targeting specific transcripts with sequences as follows were obtained from Dharmacon (Lafayette, CO) as follows: non-targeting control: CGU ACU GCU UGC GAU ACG GUU (sense strand), and CGT ACT GCT TGC GAT ACG GUU (antisense strand); GSK3 β : ACA CUA UAG UCG AGC CAA AUU (sense strand), and UUU GGC UCG ACU AUA GUG U (antisense strand); ULK1: GCA CAG AGA CCG UGG GCA AUU (sense strand), and UUG CCC ACG GUC UCU GUG CUU (antisense strand); APPL1: CAG AAU GUU CGC AGG GAA AUU (sense strand), and UUU CCC UGC GAA CAU UCU GUU (antisense strand). Cells were incubated with 220 pmol/L of each siRNA sequence with Lipofectamine RNAiMAX (LifeTechnologies) in Opti-MEM medium (Gibco) for 4 hours at 37C and 5% CO₂. After this incubation period, cells were washed and incubated in fresh cell growth medium. siRNA transfections were performed twice, 72h and 48h prior to experiments.

Whole-cell lysates and Western blotting

Western blotting using whole-cell lysates were performed as previously described (Garay et al., 2015). Cells were lysed in Laemmli sample buffer (LSB; 0.5 M Tris, pH 6.8, glycerol, 5% bromophenol blue, 10% β -mercaptoethanol, 10% SDS; BioShop, Burlington, ON) containing phosphatase and protease cocktail (1 mM sodium orthovanadate, 10 nM okadaic acid, and 20 nM

protease inhibitor, all from BioShop, Burlington, ON). Cell Lysates were then heated to 65°C for 15 min, then passed through with a 27.5-gauge syringe. Proteins within whole-cell lysates were resolved by Glycine-Tris SDS-PAGE and then transferred onto a polyvinylidene fluoride (PVDF) membrane, which was then incubated with a solution containing specific primary antibodies. Western blot signal intensity detection corresponding to either phosphorylated proteins (e.g. pGSK3 β S9), total proteins (e.g. GSK3 β), and the respective loading controls (e.g. actin) were obtained by signal integration in an area corresponding to the specific lane and band for each condition. The measurement of phosphorylation of a specific protein was obtained by normalization of the signal intensity of a phosphorylated form of a protein to that of its loading control signal, then normalization to the signal intensity similarly obtained for the corresponding total protein.

To examine phosphorylation of proteins for which no specific antibodies were available, we used the phos-tag gel system, which results in exaggeration of differences in apparent molecular weight of phosphorylated forms of specific proteins (Kinoshita et al., 2006). The phos-tag reagent was obtained from Wako (Osaka, Japan), and was used for conjugation within SDS-PAGE polymerization as per the manufacturer's instructions. After SDS-PAGE was completed, gel was submerged in MnCl₂ for chelation of remaining phos-tag moieties. Subsequently, protein intensity detection, measurement, and processing are identical to steps mentioned above.

Immunofluorescence staining

Cells grown on glass coverslips were first subjected to fixation using cold methanol, blocked in 5% bovine serum albumin (BioShop), then stained with specific primary antibodies, followed by appropriate fluorophore-conjugated secondary antibody and counter stained with DAPI. Lastly, cells were then mounted on glass slides in fluorescence mounting medium (DAKO, Carpinteria, CA).

Fluorescence microscopy

Wide-field epifluorescence was performed on an Olympus IX83 Inverted Microscope with a 100x objective, coupled to a Hamamatsu ORCA-Flash4.0 digital camera (Olympus

Canada, Richmond Hill, ON). Spinning disk confocal microscopy was performed using Quorum (Guelph, ON, Canada) Diskovery combination total internal reflection fluorescence and spinning-disc confocal microscope, operating in spinning disc confocal mode. This instrument is comprised of a Leica DMI8 microscope equipped with a 63×/1.49 NA objective with a 1.8× camera relay (total magnification 108×). Imaging was done using 488-, 561-, and 637-nm laser illumination and 527/30, 630/75, and 700/75 emission filters and acquired using a Zyla 4.2Plus sCMOS camera (Hamamatsu).

Structured illumination microscopy (SIM) was performed using a Zeiss Elyra PS.1 super-resolution inverted microscope, as previously described (Hua et al., 2017). Samples were imaged at an effective magnification of 101× (63× objective + 1.6× optovar tube lens) on an oil immersion objective. Typically, 25 to 35 slices of 0.110 μm were captured for each field of view for an imaging volume of approximately 2.75 to 3.85 μm . 488 nm, 561 nm and 643 nm laser lines were directed into the microscope optical train via a multimode fiber coupler. The lasers were passed through a diffraction grating, and a series of diffraction orders (-1, 0, +1) were projected onto the back focal plane of the objective. These wavefronts were collimated in the objective to create a three-dimensional sinusoidal illumination pattern on the sample. The diffraction grating was then rotated and translated throughout the acquisition to create patterned offset images containing encoded high spatial frequency information. Five lateral positions were acquired at each of five (72°) diffraction grating rotations for a total of 25 raw images per z-plane. SIM imaging with all lasers was carried out at exposures varying from 50 ms to 100 ms, with laser power varying between 3-10% (6-20 mW at the output), and a gain level of 60-80. Imaging parameters were adjusted iteratively to achieve the best possible equalization of pixel intensity dynamic range across channels.

Raw SIM image stacks were processed in Zen under the Structured Illumination toolbar. A series of parameters were set to generate an optical transfer function (OTF) used for 3D reconstruction. The noise filter for Wiener de-convolution was set to a value of 1.0×10^{-4} to maximize the recovery of high spatial frequency information while minimizing illumination pattern artifacts. The maximum isotropy option was left unselected to recover all available frequency information at exactly the 72° rotation angles. Negative values arising as an artifact of the Wiener filter were clipped to zero using the Baseline Cut option. Processed SIM images were

then aligned via an affine transformation matrix of pre-defined values obtained using 100 nm multicolor Tetraspeck fluorescent microspheres (ThermoFisher Scientific).

Fluorescence microscopy image analysis

Measurement of total cellular signal intensity of specific proteins or GSK3 β nuclear localization index were measured using ImageJ software (National Institutes of Health, Bethesda, MD). For total cellular measurements of specific protein signal, a region of interest corresponding to the cell outline, identified manually, was used to determine raw mean cellular fluorescence intensity. Final cellular signal intensity was obtained by subtracting background fluorescence (similarly obtained from a region on the coverslip with no cells) from the raw mean cellular fluorescence intensity, as previously described (Ross et al., 2015).

To determine GSK3 β nuclear localization index, background-subtracted mean fluorescence intensity of regions of interest within the nucleus and cytoplasm were obtained. The GSK3 β nuclear localization index is the ratio of these nuclear/cytosolic intensities. Each measurement was performed in at least three independent experiments, with > 30 cells per condition, per experiment.

Colocalization analysis was performed by determination of Manders' or Pearson's coefficients, as indicated, using the Just Another Colocalization Plugin (Bolte and Cordelières, 2006) within ImageJ, as previously described (Bone et al., 2017).

Statistical analysis

Statistical analysis was performed as previously described (Bone et al., 2017). Measurement of samples involving two experimental conditions (**Figs. 3B, 4B, 6, S2, S3A & S4B**) were analyzed by student's t-test, with $p < 0.05$ as a threshold for statistically significant difference between conditions. Measurements of samples involving one experimental parameter and more than two conditions (**Figs. 1, 2B, 4A, 4C & S1**) were analyzed by one-way ANOVA, followed by Bonferonni post-test to compare differences between conditions, with $p < 0.05$ as a threshold for statistically significant difference between conditions. Measurements of samples involving two experimental parameters (**Figures 3, 5, 7, S3B, S3C, S4C & S4D**) were analyzed

by two-way ANOVA, followed by Bonferonni post-test to compare differences between conditions, with $p < 0.05$ as a threshold for statistically significant difference between conditions.

Acknowledgements

We thank Dr. Jim Woodgett (Lunenfeld-Tanenbaum Research Institute/Mount Sinai Hospital, Toronto, ON) and Dr. Sean Egan (Hospital for Sick Children, Toronto, ON) for insightful and helpful discussions. This work was supported by a Discovery Grant from the Natural Sciences and Engineering Research Council (of Canada), an Early Researcher Award from the Ontario Ministry of Research, Innovation and Science, and a New Investigator Award from the Canadian Institutes of Health Research to C.N.A.

References

- Abrams, H. D., Rohrschneider, L. R. and Eisenman, R. N.** (1982). Nuclear location of the putative transforming protein of avian myelocytomatosis virus. *Cell* **29**, 427–39.
- Azoulay-Alfaguter, I., Elya, R., Avrahami, L., Katz, A. and Eldar-Finkelman, H.** (2015). Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. *Oncogene* **34**, 4613–4623.
- Bar-Peled, L., Schweitzer, L. D., Zoncu, R. and Sabatini, D. M.** (2012). Ragulator Is a GEF for the Rag GTPases that Signal Amino Acid Levels to mTORC1. *Cell* **150**, 1196–1208.
- Bechard, M. and Dalton, S.** (2009). Subcellular localization of glycogen synthase kinase 3 β controls embryonic stem cell self-renewal. *Mol. Cell. Biol.* **29**, 2092–104.
- Beurel, E., Grieco, S. F. and Jope, R. S.** (2015). Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. *Pharmacol. Ther.* **148**, 114–31.
- Bijur, G. N. and Jope, R. S.** (2001). Proapoptotic Stimuli Induce Nuclear Accumulation of Glycogen Synthase Kinase-3 β . *J. Biol. Chem.* **276**, 37436–37442.
- Bolte, S. and Cordelières, F. P.** (2006). A guided tour into subcellular colocalization analysis in light microscopy. *J. Microsc.* **224**, 213–32.
- Bone, L. N., Dayam, R. M., Lee, M., Kono, N., Fairn, G. D., Arai, H., Botelho, R. J. and Antonescu, C. N.** (2017). The acyltransferase LYCAT controls specific phosphoinositides and related membrane traffic. *Mol. Biol. Cell* **28**,.
- Carey, K. L., Richards, S. A., Lounsbury, K. M. and Macara, I. G.** (1996). Evidence using a green fluorescent protein-glucocorticoid receptor chimera that the Ran/TC4 GTPase mediates an essential function independent of nuclear protein import. *J. Cell Biol.* **133**, 985–96.
- Cho, K. Bin, Cho, M. K., Lee, W. Y. and Kang, K. W.** (2010). Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells. *Cancer Lett.* **293**, 230–9.
- Choudhury, A., Dominguez, M., Puri, V., Sharma, D. K., Narita, K., Wheatley, C. L., Marks, D. L. and Pagano, R. E.** (2002). Rab proteins mediate Golgi transport of caveola-

705 internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. *J.*
706 *Clin. Invest.* **109**, 1541–1550.

707 **Chu, B.-B., Liao, Y.-C., Qi, W., Xie, C., Du, X., Wang, J., Yang, H., Miao, H.-H., Li, B.-L.**
708 **and Song, B.-L.** (2015). Cholesterol transport through lysosome-peroxisome membrane
709 contacts. *Cell* **161**, 291–306.

710 **Cianfanelli, V., Fuoco, C., Lorente, M., Salazar, M., Quondamatteo, F., Gherardini, P. F.,**
711 **De Zio, D., Nazio, F., Antonioli, M., D’Orazio, M., et al.** (2014). AMBRA1 links
712 autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation
713 and degradation. *Nat. Cell Biol.* **17**, 20–30.

714 **Cormier, K. W. and Woodgett, J. R.** (2017). Recent advances in understanding the cellular
715 roles of GSK-3. *F1000Research* **6**, 167.

716 **Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. and Hemmings, B. A.** (1995).
717 Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature*
718 **378**, 785–9.

719 **Dang, C. V** (2012). MYC on the path to cancer. *Cell* **149**, 22–35.

720 **Dang, C. V, Le, A. and Gao, P.** (2009). MYC-induced cancer cell energy metabolism and
721 therapeutic opportunities. *Clin. Cancer Res.* **15**, 6479–83.

722 **Delcommenne, M., Tan, C., Gray, V., Rue, L., Woodgett, J. and Dedhar, S.** (1998).
723 Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and
724 protein kinase B/AKT by the integrin-linked kinase. *Proc. Natl. Acad. Sci. U. S. A.* **95**,
725 11211–6.

726 **Delos Santos, R., Bautista, S., Bone, L., Lucarelli, S., Dayam, R., Botelho, R. and**
727 **Antonescu, C.** (2017). Selective control of clathrin- mediated endocytosis and clathrin-
728 dependent signaling by phospholipase C and Ca²⁺ signals. *Mol. Biol. Cell, under Rev.* **28**,
729 2802–2818.

730 **Diehl, J. A., Cheng, M., Roussel, M. F. and Sherr, C. J.** (1998). Glycogen synthase kinase-
731 3 β regulates cyclin D1 proteolysis and subcellular localization. *Genes Dev.* **12**, 3499–
732 511.

733 **Ding, Q., Xia, W., Liu, J.-C., Yang, J.-Y., Lee, D.-F., Xia, J., Bartholomeusz, G., Li, Y., Pan,**

- Y., Li, Z., et al.** (2005). Erk Associates with and Primes GSK-3 β for Its Inactivation Resulting in Upregulation of β -Catenin. *Mol. Cell* **19**, 159–170.
- Doble, B. W. and Woodgett, J. R.** (2003). GSK-3: tricks of the trade for a multi-tasking kinase. *J. Cell Sci.* **116**, 1175–86.
- Fang, X., Yu, S. X., Lu, Y., Bast, R. C., Woodgett, J. R. and Mills, G. B.** (2000). Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. *Proc. Natl. Acad. Sci. U. S. A.* **97**, 11960–5.
- Feijs, K. L., Kleine, H., Braczynski, A., Forst, A. H., Herzog, N., Verheugd, P., Linzen, U., Kremmer, E. and Lüscher, B.** (2013). ARTD10 substrate identification on protein microarrays: regulation of GSK3 β by mono-ADP-ribosylation. *Cell Commun. Signal.* **11**, 5.
- Fekri, F., Delos Santos, R., Karshafian, R. and Antonescu, C.** (2016). Ultrasound microbubble treatment enhances clathrin-mediated endocytosis and fluid-phase uptake through distinct mechanisms. *PLoS One* **11**, e0156754.
- Fiol, C. J., Williams, J. S., Chou, C. H., Wang, Q. M., Roach, P. J. and Andrisani, O. M.** (1994). A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. *J. Biol. Chem.* **269**, 32187–93.
- Flinn, R. J., Yan, Y., Goswami, S., Parker, P. J. and Backer, J. M.** (2010). The Late Endosome is Essential for mTORC1 Signaling. *Mol. Biol. Cell* **21**, 833–841.
- Garay, C., Judge, G., Lucarelli, S., Bautista, S., Pandey, R., Singh, T. and Antonescu, C. N.** (2015). Epidermal growth factor-stimulated Akt phosphorylation requires clathrin or ErbB2 but not receptor endocytosis. *Mol. Biol. Cell* **26**,.
- Goñi-Oliver, P., Lucas, J. J., Avila, J. and Hernández, F.** (2007). N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. *J. Biol. Chem.* **282**, 22406–13.
- Gregory, M. A., Qi, Y. and Hann, S. R.** (2003). Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. *J. Biol. Chem.* **278**, 51606–12.
- Hann, S. R., Abrams, H. D., Rohrschneider, L. R. and Eisenman, R. N.** (1983). Proteins encoded by v-myc and c-myc oncogenes: identification and localization in acute leukemia virus transformants and bursal lymphoma cell lines. *Cell* **34**, 789–98.

763 **Hua, R., Cheng, D., Coyaud, É., Freeman, S., Di Pietro, E., Wang, Y., Vissa, A., Yip, C. M.,**
764 **Fairn, G. D., Braverman, N., et al.** (2017). VAPs and ACBD5 tether peroxisomes to the
765 ER for peroxisome maintenance and lipid homeostasis. *J. Cell Biol.* **216**, 367–377.

766 **Inoki, K., Li, Y., Zhu, T., Wu, J. and Guan, K.-L.** (2002). TSC2 is phosphorylated and
767 inhibited by Akt and suppresses mTOR signalling. *Nat. Cell Biol.* **4**, 648–657.

768 **Inoki, K., Li, Y., Xu, T. and Guan, K.-L.** (2003). Rheb GTPase is a direct target of TSC2 GAP
769 activity and regulates mTOR signaling. *Genes Dev.* **17**, 1829–34.

770 **Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C.,**
771 **Harada, Y., Stankunas, K., et al.** (2006). TSC2 Integrates Wnt and Energy Signals via a
772 Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth. *Cell* **126**,
773 955–968.

774 **Inoki, K., Kim, J. and Guan, K.-L.** (2012). AMPK and mTOR in Cellular Energy Homeostasis
775 and Drug Targets. *Annu. Rev. Pharmacol. Toxicol.* **52**, 381–400.

776 **Joep, R. S. and Johnson, G. V. .** (2004). The glamour and gloom of glycogen synthase kinase-
777 3. *Trends Biochem. Sci.* **29**, 95–102.

778 **Jung, C. H., Jun, C. B., Ro, S.-H., Kim, Y.-M., Otto, N. M., Cao, J., Kundu, M. and Kim,**
779 **D.-H.** (2009). ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy
780 machinery. *Mol. Biol. Cell* **20**, 1992–2003.

781 **Ka, M., Condorelli, G., Woodgett, J. R. and Kim, W.-Y.** (2014). mTOR regulates brain
782 morphogenesis by mediating GSK3 signaling. *Development* **141**, 4076–4086.

783 **Kalkat, M., De Melo, J., Hickman, K. A., Lourenco, C., Redel, C., Resette, D., Tamachi, A.,**
784 **Tu, W. B. and Penn, L. Z.** (2017). MYC Deregulation in Primary Human Cancers. *Genes*
785 *(Basel)*. **8**, 151.

786 **Kaushik, S., Massey, A. C. and Cuervo, A. M.** (2006). Lysosome membrane lipid
787 microdomains: novel regulators of chaperone-mediated autophagy. *EMBO J.* **25**, 3921–33.

788 **Kinoshita, E., Kinoshita-Kikuta, E., Takiyama, K. and Koike, T.** (2006). Phosphate-binding
789 tag, a new tool to visualize phosphorylated proteins. *Mol. Cell. Proteomics* **5**, 749–57.

790 **Li, Y., Xu, M., Ding, X., Yan, C., Song, Z., Chen, L., Huang, X., Wang, X., Jian, Y., Tang,**

791 **G., et al.** (2016). Protein kinase C controls lysosome biogenesis independently of
792 mTORC1. *Nat. Cell Biol.* **18**, 1065–1077.

793 **Linding, R., Jensen, L. J., Ostheimer, G. J., van Vugt, M. A. T. M., Jørgensen, C., Miron, I.**
794 **M., Diella, F., Colwill, K., Taylor, L., Elder, K., et al.** (2007). Systematic Discovery of In
795 Vivo Phosphorylation Networks. *Cell* **129**, 1415–1426.

796 **Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K. and Avruch, J.** (2005). Rheb Binds and
797 Regulates the mTOR Kinase. *Curr. Biol.* **15**, 702–713.

798 **Lüscher, B. and Eisenman, R. N.** (1988). c-myc and c-myb protein degradation: effect of
799 metabolic inhibitors and heat shock. *Mol. Cell. Biol.* **8**, 2504–12.

800 **Meares, G. P. and Jope, R. S.** (2007). Resolution of the nuclear localization mechanism of
801 glycogen synthase kinase-3: functional effects in apoptosis. *J. Biol. Chem.* **282**, 16989–
802 7001.

803 **Miller, D. M., Thomas, S. D., Islam, A., Muench, D. and Sedoris, K.** (2012). c-Myc and
804 cancer metabolism. *Clin. Cancer Res.* **18**, 5546–53.

805 **Nikolakaki, E., Coffey, P. J., Hemelsoet, R., Woodgett, J. R. and Defize, L. H.** (1993).
806 Glycogen synthase kinase 3 phosphorylates Jun family members in vitro and negatively
807 regulates their transactivating potential in intact cells. *Oncogene* **8**, 833–40.

808 **Reis, C. R., Chen, P.-H., Srinivasan, S., Aguet, F., Mettlen, M. and Schmid, S. L.** (2015).
809 Crosstalk between Akt/GSK3 β signaling and dynamin-1 regulates clathrin-mediated
810 endocytosis. *EMBO J.* **34**, 2132–46.

811 **Ross, S. E., Erickson, R. L., Hemati, N. and MacDougald, O. A.** (1999). Glycogen synthase
812 kinase 3 is an insulin-regulated C/EBP α kinase. *Mol. Cell. Biol.* **19**, 8433–41.

813 **Ross, E., Ata, R., Thavarajah, T., Medvedev, S., Bowden, P., Marshall, J. G. and**
814 **Antonescu, C. N.** (2015). AMP-activated protein kinase regulates the cell surface proteome
815 and integrin membrane traffic. *PLoS One* **10**, e0128013.

816 **Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L.**
817 **and Sabatini, D. M.** (2008). The Rag GTPases bind raptor and mediate amino acid
818 signaling to mTORC1. *Science* **320**, 1496–501.

- Saric, A., Hipolito, V. E. B., Kay, J. G., Canton, J., Antonescu, C. N. and Botelho, R. J.**
(2016). MTOR controls lysosome tubulation and antigen presentation in macrophages and dendritic cells. *Mol. Biol. Cell* **27**, 321–33.
- Saxton, R. A. and Sabatini, D. M.** (2017). mTOR Signaling in Growth, Metabolism, and Disease. *Cell* **168**, 960–976.
- Schenck, A., Goto-Silva, L., Collinet, C., Rhinn, M., Giner, A., Habermann, B., Brand, M. and Zerial, M.** (2008). The Endosomal Protein Appl1 Mediates Akt Substrate Specificity and Cell Survival in Vertebrate Development. *Cell* **133**, 486–497.
- Sekiya, S. and Suzuki, A.** (2011). Glycogen synthase kinase 3 β -dependent Snail degradation directs hepatocyte proliferation in normal liver regeneration. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 11175–80.
- Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A. and Cantley, L. C.** (2004). The LKB1 tumor suppressor negatively regulates mTOR signaling. *Cancer Cell* **6**, 91–9.
- Smith, K. P., Byron, M., O’Connell, B. C., Tam, R., Schorl, C., Guney, I., Hall, L. L., Agrawal, P., Sedivy, J. M. and Lawrence, J. B.** (2004). c-Myc localization within the nucleus: evidence for association with the PML nuclear body. *J. Cell. Biochem.* **93**, 1282–96.
- Stadler, S. C., Vincent, C. T., Fedorov, V. D., Patsialou, A., Cherrington, B. D., Wakshlag, J. J., Mohanan, S., Zee, B. M., Zhang, X., Garcia, B. A., et al.** (2013). Dysregulation of PAD4-mediated citrullination of nuclear GSK3 β activates TGF- β signaling and induces epithelial-to-mesenchymal transition in breast cancer cells. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 11851–6.
- Stambolic, V. and Woodgett, J. R.** (1994). Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. *Biochem. J.* **303 (Pt 3)**, 701–4.
- Strambio-De-Castillia, C., Niepel, M. and Rout, M. P.** (2010). The nuclear pore complex: bridging nuclear transport and gene regulation. *Nat. Rev. Mol. Cell Biol.* **11**, 490–501.
- Stretton, C., Hoffmann, T. M., Munson, M. J., Prescott, A., Taylor, P. M., Ganley, I. G. and Hundal, H. S.** (2015). GSK3-mediated raptor phosphorylation supports amino-acid-

dependent mTORC1-directed signalling. *Biochem. J.* **470**, 207–221.

Sutherland, C. (2011). What Are the *bona fide* GSK3 Substrates? *Int. J. Alzheimers. Dis.* **2011**, 1–23.

Sutherland, C., Leighton, I. A. and Cohen, P. (1993). Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. *Biochem. J.* **296 (Pt 1)**, 15–9.

Suzuki, T., Bridges, D., Nakada, D., Skiniotis, G., Morrison, S. J., Lin, J. D., Saltiel, A. R. and Inoki, K. (2013). Inhibition of AMPK Catabolic Action by GSK3. *Mol. Cell* **50**, 407–419.

Taelman, V. F., Dobrowolski, R., Plouhinec, J.-L., Fuentealba, L. C., Vorwald, P. P., Gumper, I., Sabatini, D. D. and De Robertis, E. M. (2010). Wnt Signaling Requires Sequestration of Glycogen Synthase Kinase 3 inside Multivesicular Endosomes. *Cell* **143**, 1136–1148.

Tang, Q.-Q., Gronborg, M., Huang, H., Kim, J.-W., Otto, T. C., Pandey, A. and Lane, M. D. (2005). Sequential phosphorylation of CCAAT enhancer-binding protein by MAPK and glycogen synthase kinase 3 is required for adipogenesis. *Proc. Natl. Acad. Sci.* **102**, 9766–9771.

Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C. and Blenis, J. (2003). Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. *Curr. Biol.* **13**, 1259–68.

Thomas, L. R. and Tansey, W. P. (2011). Proteolytic Control of the Oncoprotein Transcription Factor Myc. In *Advances in cancer research*, pp. 77–106.

Thornton, T. M., Pedraza-Alva, G., Deng, B., Wood, C. D., Aronshtam, A., Clements, J. L., Sabio, G., Davis, R. J., Matthews, D. E., Doble, B., et al. (2008). Phosphorylation by p38 MAPK as an Alternative Pathway for GSK3 Inactivation. *Science (80-.)*. **320**, 667–670.

Tsujio, I., Tanaka, T., Kudo, T., Nishikawa, T., Shinozaki, K., Grundke-Iqbal, I., Iqbal, K. and Takeda, M. (2000). Inactivation of glycogen synthase kinase-3 by protein kinase C delta: implications for regulation of tau phosphorylation. *FEBS Lett.* **469**, 111–7.

Vanlandingham, P. A. and Ceresa, B. P. (2009). Rab7 regulates late endocytic trafficking

downstream of multivesicular body biogenesis and cargo sequestration. *J. Biol. Chem.* **284**, 12110–24.

Wiechens, N. and Fagotto, F. (2001). CRM1- and Ran-independent nuclear export of β -catenin. *Curr. Biol.* **11**, 18–28.

Woodgett, J. R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. *EMBO J.* **9**, 2431–8.

Wu, D. and Pan, W. (2010). GSK3: a multifaceted kinase in Wnt signaling. *Trends Biochem. Sci.* **35**, 161–168.

Zeng, X., Huang, H., Tamai, K., Zhang, X., Harada, Y., Yokota, C., Almeida, K., Wang, J., Doble, B., Woodgett, J., et al. (2008). Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. *Development* **135**, 367–75.

Zhou, B. P., Deng, J., Xia, W., Xu, J., Li, Y. M., Gunduz, M. and Hung, M.-C. (2004). Dual regulation of Snail by GSK-3 β -mediated phosphorylation in control of epithelial–mesenchymal transition. *Nat. Cell Biol.* **6**, 931–940.

Zmijewski, J. W. and Jope, R. S. (2004). Nuclear accumulation of glycogen synthase kinase-3 during replicative senescence of human fibroblasts. *Aging Cell* **3**, 309–17.

Zoncu, R., Perera, R. M., Balkin, D. M., Pirruccello, M., Toomre, D. and De Camilli, P. (2009). A Phosphoinositide Switch Controls the Maturation and Signaling Properties of APPL Endosomes. *Cell* **136**, 1110–1121.

Zoncu, R., Bar-Peled, L., Efeyan, A., Wang, S., Sancak, Y. and Sabatini, D. M. (2011). mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. *Science* **334**, 678–83.

Figure Legends

Figure 1. mTORC1 inhibition decreases c-myc and snail expression in a GSK3 β -dependent manner. (A-B) RPE cells were treated with 1 μ M Rapamycin, in the presence or absence of 10 μ M CHIR 99021 for the indicated times (A) or 1 h (B). Shown are representative immunoblots of whole-cell lysates probed with anti-c-myc (A), anti-snail (B) or anti-clathrin heavy chain (load) antibodies. Also shown are mean c-myc levels $\pm$ SE, n = 6, * p < 0.05 (A), or mean snail levels n=3; *, p < 0.05 (B), relative to that in the control conditions (no inhibitor treatment). (C) RPE cells were transfected with siRNA targeting GSK3 β or non-targeting siRNA (control), then treated with either 10 μ M LY294002, 5 μ M Akti-1/2, or 1 μ M Rapamycin for 1 h. Shown are representative immunoblots of whole-cell lysates probed with anti-c-myc or anti-actin (load) antibodies, as well as mean c-myc levels, n = 4; * p < 0.05, relative to that in the control conditions (no inhibitor treatment).

Figure 2. Inhibition of PI3K/Akt/mTORC1 signals promotes GSK3 β nuclear localization. (A) Representative images obtained by widefield epifluorescence microscopy of control RPE cells (no inhibitor treatment) stained to detect endogenous GSK3 β or c-myc, with DAPI stain to identify the nucleus, scale = 20 μ m. (B) RPE cells were treated with either 10 μ M LY294002, 5 μ M Akti-1/2, or 1 μ M Rapamycin for 1 h, then fixed and stained to detect endogenous GSK3 β . Shown (left panel) are micrographs obtained by widefield epifluorescence microscopy representative of 3 independent experiments, scale = 20 μ m. Also shown for each condition as ‘GSK3 β overlay’ are sample cellular and nuclear outlines, and a box corresponding to a magnified image of a single cell. Also shown (right panel) is the mean GSK3 β nuclear localization index $\pm$ SE (n = 3, >30 cells per condition per experiment); *, p < 0.05 relative to control conditions (no inhibitor treatment).

Figure 3. Rapamycin-induced GSK3 β nuclear localization is Ran-dependent. (A) RPE cells were transfected with plasmids encoding HA-tagged wild-type (WT), T24N or G19V Ran, then treated with 1 μ M Rapamycin for 1 h, followed by detection of endogenous GSK3 β and exogenous HA-tagged Ran proteins. Shown (top panel) are micrographs obtained by widefield epifluorescence microscopy representative of 3 independent experiments, scale = 20 μ m. Also

shown for each condition as ‘GSK3 β overlay’ are sample cellular and nuclear outlines, and a box corresponding to a magnified image of a single cell. Also shown (bottom panel) is the mean GSK3 β nuclear localization index $\pm$ SE (n = 3, >30 cells per condition per experiment); *, p < 0.05 relative to control conditions (no inhibitor treatment).

Figure 4. mTORC1 integrates multiple signals to control GSK3 β nuclear localization. RPE cells were treated with either 100 μ M A769662, 5 μ M Compound C, or 1 μ M Rapamycin, alone or in combination for 1h (**A**), or 1 μ M Concanamycin for 1h (**B**), or incubated in amino acid-free EBSS media for 2h (**C**). Shown (left panels) in each case are micrographs obtained by widefield epifluorescence microscopy representative of 3 independent experiments, scale = 20 μ m. Also shown for each condition as ‘GSK3 β overlay’ are sample cellular and nuclear outlines, and a box corresponding to a magnified image of a single cell. Also shown (right panels) are the mean GSK3 β nuclear localization indices $\pm$ SE (n = 3, >30 cells per condition per experiment); *, p < 0.05 relative to control conditions (no inhibitor treatment).

Figure 5. GSK3 β S9 phosphorylation is not required for GSK3 β nuclear localization induced by inhibition of PI3K-Akt-mTORC1 signals. (**A**) RPE cells were treated either 10 μ M LY294002, 5 μ M Akti-1/2, or 1 μ M Rapamycin for 1 h. Shown are representative immunoblots of whole-cell lysates probed with anti-pS9 GSK3 β or anti-total GSK3 β antibodies. Also shown are mean anti-pS9 GSK3 β levels (normalized to total GSK3 β) $\pm$ SE, n = 3, * p < 0.05, relative to that in the control conditions (no inhibitor treatment). (**B**) RPE cells were transfected with plasmids encoding HA-tagged wild-type (WT) or S9A GSK3 β then treated with 5 μ M Akti-1/2 for 1 h, followed by detection of exogenous HA-GSK3 β proteins. Shown (top panel) are micrographs obtained by widefield epifluorescence microscopy representative of 3 independent experiments, scale = 20 μ m. Also shown for each condition as ‘HA-GSK3 β overlay’ are sample cellular and nuclear outlines, and a box corresponding to a magnified image of a single cell. Also shown (bottom panel) is the mean HA-GSK3 β nuclear localization index $\pm$ SE (n = 3, >30 cells per condition per experiment); *, p < 0.05 relative to control conditions (no inhibitor treatment).

Figure 6. GSK3 β exhibits partial localization to several distinct endomembrane compartments. (A-C) RPE cells were fixed and stained to detect endogenous GSK3 β , together with either endogenous APPL1 (A), EEA1 (B), or LAMP1 (C). Shown are representative images obtained by spinning-disc confocal microscopy, corresponding to a z-section through the middle of the cell, scale 20 μ m (left panels). Also shown (right panels) are the mean $\pm$ SE of Manders' coefficient to measure overlap of GSK3 β signals with either APPL1 (A), EEA1 (B), or LAMP1 (C) (n = 3, > 30 cells per condition per experiment). For each image set, Manders' coefficients were calculated for actual images (labelled 'actual'), as well as images in which the spatial position of one of the channels had been randomized (labelled 'rand.'), to allow resolution of specific GSK3 β localization to various endomembrane compartments from random overlap of signals in a field densely populated with fluorescent objects. (D) RPE cell samples prepared similarly as in (C) were subjected to structured illumination microscopy (SIM). Shown are representative micrographs of (endogenous) GSK3 β and LAMP1 staining morphology, scale 5 μ m (top panels) or 1 μ m (bottom panel).

Figure 7. Rab7 controls GSK3 β nuclear localization and GSK3 β -dependent c-myc expression. RPE cells were transfected with plasmids encoding dsRed-tagged wild-type (WT) or T22N Rab7, then treated with 1 μ M rapamycin for 1 h, followed by detection of endogenous GSK3 β (A) or c-myc (B). Shown (left panels) are micrographs obtained by widefield epifluorescence microscopy representative of 3 independent experiments, scale = 20 μ m. Also shown for each condition as 'GSK3 β overlay' (A) or 'c-myc overlay' (B) are sample cellular and nuclear outlines, and a box corresponding to a magnified image of a single cell. Also shown (right panels) is the mean $\pm$ SE of the GSK3 β nuclear localization index (A) (n = 3, >30 cells per condition per experiment) or total cellular c-myc level (B) (n = 3, >30 cells per condition per experiment); *, $p < 0.05$ relative to control conditions (no inhibitor treatment).

Figure 1




Figure 2




Figure 3





Figure 4




Figure 5




Figure 6




Figure 7

